2-(2-Formamidothiazole-4-Yl)-2-Methoxyimino Acetic Acid

Industrial-scale synthesis of cefepime dihydrochloride monohydrate, a fourth-generation parenteral cephalosporin with anti-pseudomonal activity, proceeds through the acylation of 3′-[(1-methylpyrrolidinio)methyl]-7-aminoceph-3-em-4-carboxylate hydrochloride (7-ACP·HCl) with the active mixed anhydride of 2-(2-formamidothiazole-4-yl)-2-methoxyimino acetic acid. The compound, supplied as a crystalline powder with an assay of ≥98.5 % (HPLC, area normalization at 270 nm), is first converted to the corresponding acid chloride via reaction with phosphorus pentachloride in dichloromethane at −5 °C to 0 °C, or more commonly activated as the thioester with 2-mercaptobenzothiazole and dicyclohexylcarbodiimide (DCC) in tetrahydrofuran. The acylation is carried out at −10 °C under rigorous exclusion of atmospheric moisture; the formamido group remains intact during coupling, preventing the generation of free amine nucleophiles that could attack the β-lactam ring. After aqueous work-up at pH 2.5–3.0, the protected intermediate, (6R,7R)-7-[(Z)-2-(2-formamidothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(1-methylpyrrolidinio)methyl]-ceph-3-em-4-carboxylate, is isolated by precipitation with acetone. Deprotection of the formyl moiety is achieved with methanolic hydrogen chloride (1.5–2.0 equivalents) at 20–25 °C over 4–6 hours, liberating the free 2-aminothiazole chromophore with a bathochromic shift to λmax 256 nm. The crude cefepime dihydrochloride is crystallized from aqueous acetone acidified with hydrochloric acid to yield the monohydrate, whose water content is confirmed by Karl Fischer titration (3.8–4.5 % w/w, complying with USP monograph 0988). Residual solvent limits are validated against ICH Q3C guideline: dichloromethane ≤600 ppm, tetrahydrofuran ≤720 ppm, acetone ≤5000 ppm. Throughout the synthesis, in-process controls monitor the disappearance of the starting thiazole acid by reverse-phase HPLC on an octadecylsilyl silica column (L1 packing, 5 µm, 250×4.6 mm) with a mobile phase of phosphate buffer pH 3.0 / acetonitrile gradient, detection at 254 nm. Critical quality attributes of the final API include bacterial endotoxins <0.10 EU/mg (USP <85>), heavy metals ≤20 ppm (USP <231> Method II), and specific rotation [α]D²⁵ between +39° and +45° (c=1, water). The yield from the thiazole acid typically falls in the range 68–72 % based on commercially reproducible batch records of 100–500 kg scale; batch-to-batch variance is most sensitive to moisture ingress during mixed anhydride formation, where water content above 0.05 % w/w in the solvent shifts the E/Z isomer ratio unfavorably, generating up to 3.2 % of the anti-isomer impurity.

Selection of the activation strategy for the formamidothiazole acetic acid has a decisive impact on impurity A ((E)-isomer) levels and overall yield. Table 1 collates pilot-scale data.

Note: Yields represent isolated yields after drying at 40 °C under vacuum. Impurity A determined by HPLC area normalization. EDC/HOBt method yielded lowest epimerization but required aqueous extraction to remove DMF, necessitating a hold-time control to prevent β-lactam hydrolysis.

Which Process Parameters Govern the Z-Isomer Purity When the Protected Thiazole Acid is Attached to Cefpirome’s 7-Amino Cephalosporanic Acid Intermediate?

Cefpirome sulfate, designated in the European Pharmacopoeia monograph 01/2018:2032, is a fourth-generation oxyimino-cephalosporin with a 3′-cyclopentenopyridine substituent. Its synthesis employs 7-amino-3′-[(2,3-cyclopenteno-1-pyridinio)methyl]-ceph-3-em-4-carboxylate hydrochloride (7-CP·HCl), which couples with the activated form of 2-(2-formamidothiazole-4-yl)-2-methoxyimino acetic acid. The formamido-protected intermediate poses unique stereochemical challenges because the 7-CP nucleus exhibits steric crowding near the 7β-amino group, slowing acylation kinetics and increasing the risk of E-isomer formation if the mixed anhydride is added too rapidly. At pilot scale in a glass-lined reactor (500 L, anchor agitator at 85 rpm), optimal selectivity is achieved by feeding a 20 % w/v solution of the pivaloyl mixed anhydride in dimethylacetamide at a constant rate of 3.5 kg/h, maintaining the reaction mass at −8 °C ± 2 °C. The pH is held at 4.8–5.2 by automatic titration with triethylamine. Under these conditions, the Z-isomer ratio exceeds 98.5:1.5 as measured by HPLC (column: L7, 5 µm, 150×4.0 mm, mobile phase methanol/phosphate buffer pH 5.0 15:85 v/v). Thermal hazard assessment by differential scanning calorimetry indicates that the formamido intermediate in the wet cake undergoes exothermic deformylation with an onset at 132 °C and an energy release of −610 J/g; therefore, drying is restricted to a vacuum tray dryer with a jacket temperature not exceeding 45 °C. Deprotection with 1.8 equivalents of methanolic HCl at 20 °C for 5 hours liberates the 2-aminothiazole group. The subsequent sulfate salt formation in aqueous acetone at pH 1.8–2.2 precipitates cefpirome sulfate with a purity of ≥99.0 %. Industrial batch records from dedicated production lines reveal a recurrent bottleneck during the final filtration: needle-like crystals of the sulfate salt blind the PEEK cloth of the centrifuge if the cooling ramp exceeds −0.2 °C/min; a controlled linear ramp from 20 °C to −5 °C over 125 minutes is mandatory to obtain a granular habit that permits a filtration rate of 8–10 L/min·m². Residual dimethylacetamide is controlled below 180 ppm (ICH Q3C class 2). The overall yield from the thiazole acid is 61–65 %.

Cefquinome sulfate, a fourth-generation cephalosporin for veterinary use in bovine respiratory disease and mastitis, is accessed by coupling 2-(2-formamidothiazole-4-yl)-2-methoxyimino acetic acid to 7-amino-3’-(5,6,7,8-tetrahydroquinolin-1-ium-1-methyl)ceph-3-em-4-carboxylate. The tetrahydroquinolinium side chain introduces a primary amine-like character that can accelerate β-lactam ring opening if the reaction pH drops below 3.5; thus, the acylation is buffered with sodium bicarbonate to maintain a pH of 5.6–5.8 throughout the addition of the mixed anhydride, which is generated using ethyl chloroformate in dichloromethane at −15 °C. The protected coupling product crystallizes directly from the reaction mixture upon dilution with water at 5 °C, and the formamido group is removed with 1.4 equivalents of sulfuric acid in methanol at 30 °C for 3 hours, simultaneously forming the hemisulfate salt. VICH GL11 (Residual Solvents in Veterinary Medicinal Products) is applied to control dichloromethane ≤100 ppm and methanol ≤3000 ppm in the finished API. Critical process hazard: the methoxyimino moiety is susceptible to isomerization upon contact with strong alkali; any post-reaction wash with sodium hydroxide solution must be strictly avoided. When the pH transiently exceeds 8.0 during equipment cleaning, a 7–12 % drop in Z-isomer purity has been documented. The final product, white to off-white crystalline powder, must comply with the veterinary-specific monograph requirements for cefquinome sulfate, including a heavy metals limit of ≤10 ppm (Ph.Eur. method 2.4.8) and a water content of 2.8–3.4 % by Karl Fischer. Typical yield from the thiazole acid: 58–63 %. Table 2 summarizes the statutory acceptance criteria for the cefquinome sulfate API lot release.

Reference Standard for Impurity Identification in Cefepime Monographs

Pharmacopoeial monographs for cefepime require chromatographic peak identification of structurally related substances using a qualified reference standard. 2-(2-Formamidothiazole-4-yl)-2-methoxyimino acetic acid is employed as the primary process-related impurity standard for Impurity E (the formamido intermediate itself) and as a precursor for synthesizing the (E)-isomer. The material for this application is purified by preparative HPLC on a C18 column, 10 µm, 50×250 mm, eluting with 0.1 % formic acid / acetonitrile 85:15 v/v, followed by lyophilization to achieve an assay of ≥99.9 % by qNMR (internal standard maleic acid, DMSO-d₆). The isolated solid is characterized by its melting point 178–181 °C (dec.), high-resolution mass spectrum with [M+H]⁺ at m/z 244.0392, and a UV maximum at 288 nm in methanol. A 10 mg aliquot dissolved in 100 mL of diluent (mobile phase) serves as the system suitability solution for the USP cefepime hydrochloride Related Compounds test, confirming resolution between cefepime and Impurity E of not less than 2.0. Failure to use a reference standard with a formamido group hydrolyzed below 0.05 % results in overestimation of the active 2-aminothiazole impurity. Handling note: the standard must be stored in tightly closed containers under nitrogen at 2–8 °C, as humidity-promoted hydrolysis converts the formamido thiazole to the free amine within 72 hours at 60 % RH.

Structure-activity relationship studies of oxyimino-aminothiazole cephalosporins frequently employ 2-(2-formamidothiazole-4-yl)-2-methoxyimino acetic acid as a starting block for parallel synthesis of 7-acylamino side chains. In a typical bench-scale library generation, the formamido acid is coupled to a diverse set of 3′-functionalized 7-ACA derivatives (such as vinyl, substituted thiomethyl, or quaternary ammonium groups) using the 1-hydroxybenzotriazole/EDC method in dry N,N-dimethylformamide at 0–5 °C. The formamido group is retained during the SAR study because it blocks non-specific binding in preliminary microbiological assays, and its removal with dilute HCl in dioxane (4 M, 25 °C, 2 hours) after initial screening reveals the active aminothiazole form. Published data for this specific configuration indicates that the methoxyimino Z-isomer configuration is retained under these conditions as long as the reaction is shielded from ambient light; exposure to 254 nm UV for >4 hours in solution raises the E-isomer fraction to 12 %. Isolated yields across 24-member libraries ranged from 45–78 % depending on the bulkiness of the 3′-substituent, with the lowest yields observed for cephalosporins bearing sterically hindered N-alkyl pyridinium groups. The compound’s utility in medicinal chemistry is further extended by its compatibility with immobilized carbodiimide solid-phase coupling strategies, where the formamido group remains resistant to the mildly acidic cleavage conditions (5 % TFA in dichloromethane) used for resin release.

When the Thiazole Acid is Introduced via Continuous Flow Processing for Cefoselis Sulfate, the Residence Time in the Microreactor Determines the Yield Window

Cefoselis sulfate, a parenteral cephalosporin active against both Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), contains a 3′-sulfamoylmethyl substituent that imparts exceptional aqueous solubility. Its synthesis exploits the same formamidothiazole-methoxyimino acetic acid for the 7β-acylamido side chain, but the highly polar sulfonamide intermediate accelerates β-lactam degradation under prolonged batch contact. Published data for this specific configuration is limited; however, pilot studies using a Corning Advanced-Flow reactor (G1 SiC module, internal volume 10 mL) demonstrate that the mixed pivaloyl anhydride of the thiazole acid, when reacted with the 7-amino-3′-sulfamoylmethylcephem nucleus in a water/acetonitrile (5:1 v/v) solvent at −5 °C with a total flow rate of 2.0 mL/min (residence time 5 minutes), achieves a coupling conversion of 82 % and a Z-isomer purity of 98.7 %. Increasing residence time to 8 minutes raises conversion to 91 % but increases the hydrolytic opening of the β-lactam ring, yielding 3.5 % of the penicilloic acid degradation product. After the flow acylation step, the formamido group is deprotected with methanolic HCl in a second continuous stirred-tank reactor at 25 °C with a mean residence time of 4.2 minutes. The isolated cefoselis sulfate exhibits an endotoxin level of ≤0.05 EU/mg and a residual solvent profile within ICH Q3C limits. Because the microreactor’s heat transfer efficiency (−5 °C ± 0.5 °C) dramatically reduces local hot spots, scaling the flow process to commercial production eliminates the batch-mode impurity excursions that arise when the Schlenk-type reactor jacket deviates by more than ±3 °C.